{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:40:17Z","timestamp":1770961217881,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"7P2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3852,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:p>The emergency department is becoming an increasingly important setting for the management of community\u2010acquired pneumonia (CAP). This trend reflects the shortened hospital stays and decreased mortality among elderly hospitalized patients resulting from rapid administration of antimicrobials. In addition, decisions about the site of care (inpatient vs outpatient) and antimicrobial therapy frequently are made in the emergency department. Recent research and subsequent clinical guidelines may help with these decisions. For example, recently issued guidelines, such as those of the Infectious Diseases Society of America and the American Thoracic Society, suggest that selection of antimicrobials for CAP (which is typically empiric) should be based on the potential pathogens and likelihood of antimicrobial resistance. Macrolides and tetracyclines are recommended in younger patients with mild\u2010to\u2010moderate disease. Patients with more severe disease and those at risk for drug\u2010resistant pathogens should be treated with broad\u2010spectrum therapy, such as a newer fluoroquinolone or a cephalosporin plus a macrolide. When hospitalization is required, early switch from intravenous to oral therapy, followed by early discharge, can be a highly successful strategy. Antimicrobials that are available in both intravenous and oral formulations, such as the newer fluoroquinolones (e.g., levofloxacin and gatifloxacin), can simplify switch therapy. For outpatients, an initial long\u2010acting parenteral dose of azithromycin, ceftriaxone, or levofloxacin followed by oral therapy is an effective protocol. In addition, use of a prediction rule to identify low\u2010risk patients with CAP may help guide decisions about the need for hospital admission.<\/jats:p>","DOI":"10.1592\/phco.21.10.95s.34532","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T06:06:08Z","timestamp":1086761168000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Directions in Antiinfective Therapy for Community\u2010Acquired Pneumonia in the Emergency Department"],"prefix":"10.1002","volume":"21","author":[{"given":"Gregory J.","family":"Moran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550230056037"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.1.1"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1021315"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/313954"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199009000-00004"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.9.970"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.5.1487"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.10.1399"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.40.5.1208","article-title":"Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30\u2014center national surveillance study","volume":"40","author":"Doern G.V.","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_11_2","unstructured":"ThornsberryC. CritchleyI.A. MaurizY. KahnJ. PiazzaG. SahmD.F.Longitudinal analysis of resistance among Streptococcus pneumoniae (SP) isolated from 100 geographically distributed institutions in the United States during the 1997\u20131998 and 1998\u20131999 respiratory seasons. Presented at the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 27 1999."},{"key":"e_1_2_1_12_2","first-page":"365","article-title":"Multistate population\u2010based assessment of drug\u2010resistant S. pneumoniae mortality [abstr]","volume":"25","author":"Feikin D.","year":"1997","journal-title":"Clin Infect Dis"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0506.990603"},{"key":"e_1_2_1_14_2","unstructured":"SelmanL.J. MayfieldD.C. ThornsberryC. MaurizY.R. SahmD.F.Changes in single\u2010 and multiple\u2010drug resistance among Streptococcus pneumoniae over three years (1997\u20132000). Presented at the 40th interscience conference on antimicrobial agents and chemotherapy Toronto Canada September 1720 2000."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508243330802"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.5.1418"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00002"},{"key":"e_1_2_1_18_2","volume-title":"Tequin (gatifloxacin) product information","author":"Bristol\u2010Myers Squibb Company","year":"1999"},{"issue":"243","key":"e_1_2_1_19_2","first-page":"288","article-title":"A prediction rule to identify low\u2010risk patients with community\u2010acquired pneumonia","volume":"336","author":"Fine M.J.","year":"1997","journal-title":"N Engl J Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.6.749"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.10.95S.34532","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.10.95S.34532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:40:07Z","timestamp":1761039607000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.10.95S.34532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":19,"journal-issue":{"issue":"7P2","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1592\/phco.21.10.95S.34532"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.10.95s.34532","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}